Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (Nivolumab) and FPA008 in Six Tumor Types Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational programmed death-1 immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor. [Bristol-Myers Squibb Company] Press Release TapImmune Announces Phase II Clinical Trials Collaboration with VGTI Florida to Advance Breast and Ovarian Cancer Vaccines TapImmune, Inc. announced a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), forming a partnership to advance TapImmune’s proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers. [TapImmune, Inc.] Press Release Transposagen Biopharmaceuticals Enters into Research Collaboration and Worldwide License Agreement with Janssen for Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Therapies Transposagen Biopharmaceuticals, Inc. announced they have entered into a research collaboration and worldwide license agreement with Janssen Biotech, Inc. to develop allogeneic CAR-T. CAR-T therapies have shown promise in early human clinical trials for the treatment of blood cancers and allogeneic CAR-Ts have the potential for use as off-the-shelf cancer treatments without the need of matching donor with recipient. [Transposagen Biopharmaceuticals, Inc.] Press Release Theravectys Provides Update on Its Phase I/II Lentiviral Vector-Based Therapeutic Vaccine Trial Theravectys reports promising preliminary results in the first-ever vaccination trial conducted with lentiviral vectors. The randomized, placebo-controlled trial currently enrolls 38 HIV-positive patients under highly active antiretroviral therapy in 12 clinical sites in France and Belgium and aims at comparing the safety, tolerability and immunogenicity of its therapeutic vaccine candidate at three different doses versus placebo. [Theravectys SA] Press Release Health Canada Clears Immunovaccine to Conduct Phase II Clinical Trial of DPX-Survivac in Recurrent Lymphoma Immunovaccine Inc. announced that it has received clearance from Health Canada to conduct a Phase II clinical study of DPX-Survivac in patients with diffuse large B cell lymphoma. [Immunovaccine Inc.] Press Release Juno T Cell Therapy for Leukemia Granted FDA Breakthrough Therapy Designation Juno Therapeutics announced that the FDA has granted breakthrough therapy designation to the company’s JCAR015 chimeric antigen receptor product candidate. The designation applies for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia and was filed by Juno’s collaboration partner, Memorial Sloan Kettering Cancer Center, where Phase I clinical trials are currently underway. [Juno Therapeutics Inc.] Press Release Cell Therapy Trial Offers New Hope to Liver Disease Patients Researchers from the University of Edinburgh have received funding to start testing the therapy in patients within the next year. It will be the world’s first clinical trial of a new type of cell therapy to treat liver cirrhosis, a common disease where scar tissue forms in the organ as a result of long-term damage. [MRC Centre for Regenerative Medicine] Press Release Cord Blood Registry Sponsors 2014 World Stem Cell Summit Cord Blood Registry® announced that the company is a platinum sponsor of the 10th Annual World Stem Cell Summit, the largest global meeting of stem cell science and regenerative medicine stakeholders. [Cord Blood Registry®] Press Release Mount Sinai Researchers Awarded Grant to Find New Stem Cell Therapies for Vision Recovery The National Eye Institute, a division of the National Institutes of Health, has awarded researchers at the Icahn School of Medicine at Mount Sinai a five-year grant totaling $1 million that will support an effort to re-create a patients’ ocular stem cells and restore vision in those blinded by corneal disease. [The Mount Sinai Hospital (EurekAlert)] Press Release |